Alefacept, which in 2003 was the first biologic agent approved in the US for the treatment of moderate to severe chronic plaque psoriasis, appears to be a long-term option for certain patients. Reuters Health Information
A disturbing number of trials are lacking rigorous statistical methods in both their design and analysis, researchers demonstrate in a thought-provoking new study. Medscape Medical News
Nonbullous congenital ichthyosiform erythroderma (NBCIE) is not recognized as a risk factor for skin cancer. Maybe it should be. The British Journal of Dermatology
